Effects of short-term administration of metronidazole on the subgingival microflora.
The effect of a 5-day course of systemic metronidazole was investigated in 11 recall maintenance patients over a period of 3 months. Crevicular fluid flow, bleeding on probing, pocket depth, and composition of the subgingival microbiota as observed by dark-field microscopy, were measured. The study design allowed patients to act as their own controls. At baseline 1 (day 0), each patient had a randomly assigned quadrant scaled and root-planed, and received oral hygiene instruction. Microbiological and clinical parameters were measured at baseline 1 (before treatment) and at 3, 6, and 12 weeks in both the root-planed and a designated no-treatment quadrant. At baseline 2 (12 weeks), the contralateral quadrant was scaled and root-planed, and the oral hygiene instruction was reinforced. At this appointment, each patient was given 15 metronidazole tablets (250 mg), 1 to be taken 3 times per day for 5 days. At the end of this period, patients were seen 1-2 h after taking their last tablet, and blood and crevicular fluid samples were taken to determine the concentration of metronidazole by microbiological assay in the serum and crevicular fluid. Microbiological and clinical parameters were measured at baseline 2 (before treatment) and at 13, 15, 18, and 24 weeks in both the root-planed and designated non-root-planed (metronidazole only) quadrants. Results demonstrated that in this group of recall maintenance patients, metronidazole was no more effective than root-planing alone in reducing the relative % of total motile organisms and spirochetes in 5-8 mm pockets. Crevicular fluid flow was, however, significantly reduced for 11 weeks; serum and crevicular fluid levels of metronidazole were similar 1 to 2 h after drug ingestion.
D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects*; D012534:Dental Scaling; D005260:Female; D005881:Gingiva / Q000382:microbiology*; D005883:Gingival Crevicular Fluid / Q000382:microbiology; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D010514:Periodontal Pocket / Q000188:drug therapy / Q000382:microbiology*; D010518:Periodontitis / Q000382:microbiology*; D013357:Subgingival Curettage; D014092:Tooth Root / Q000601:surgery
D008795:Metronidazole